Idenix Pharmaceuticals (IDIX) Reports In-Line Q4 Loss of 17c/Share
Tweet Send to a FriendGet Alerts IDIX Hot Sheet
Price: $5.20 +0.39%
EPS Growth %: +5.6%
Financial Fact:
Net loss: -30.75M
Today's EPS Names:
MPAA, LTON, KFY, More
EPS Growth %: +5.6%
Financial Fact:
Net loss: -30.75M
Today's EPS Names:
MPAA, LTON, KFY, More
Trade IDIX Now!
Idenix Pharmaceuticals (NASDAQ: IDIX) reported Q4 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $327 thousand versus the consensus estimate of $740 thousand.
For earnings history and earnings-related data on Idenix Pharmaceuticals (IDIX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For earnings history and earnings-related data on Idenix Pharmaceuticals (IDIX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Five Below (FIVE) Tops Q1 EPS by 1c, Boosts FY13 Outlook
- Alco Stores (ALCS) Widens Q1 Loss to 51c/Share
- Linktone Ltd. (LTON) Q1 Profit Slips to 10c/ADS
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
